Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4629-4638

  Evans, Tracey ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Bevacizumab; Biomarkers; Review; Treatment emergent adverse events; Vascular endothelial growth factor; VEGF

Indexed keywords

AFLIBERCEPT; AMGEN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPERTENSION; INCIDENCE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SURVIVAL TIME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; HYPERTENSION; LUNG NEOPLASMS;

EID: 84872657330     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Van Meter ME and Kim ES: Bevacizumab: current updates in treatment. Curr Opin Oncol 22(6): 586-591, 2010.
2. Gressett SM and Shah SR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43(3): 490-501, 2009.
3. AVASTIN® (bevacizumab) Solution for intravenous infusion [package insert]. South San Francisco, CA: Genentech, Inc., 2011.
4. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267(16): 10931-10934, 1992.
5. Folkman J and Klagsbrun M: Vascular physiology. A family of angiogenic peptides. Nature 329(6141): 671-672, 1987.
6. Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2): 328-335, 2005.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-42, 2004.
8. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010): 899-909, 1995.
9. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA and Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: Sobering results. J Clin Oncol 19(6): 1734-1742, 2001.
10. Carney DN: Lung cancer-time to move on from chemotherapy. N Engl J Med 346(2): 126-128, 2002.
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355(24): 2542-2550, 2006.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353(2): 123-132, 2005.
13. Pirker R, Pereira JR, Szczesna A, von PJ, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de MF, Eberhardt W, Goddemeier T, Emig M and Gatzemeier U: Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373(9674): 1525-1531, 2009.
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004.
15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500, 2004.
16. Pirker R, Pereira JR, von PJ, Krzakowski M, Ramlau R, Park K, de MF, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von HA, Celik I and O'Byrne KJ: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1): 33-42, 2012.
17. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, III, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22(11): 2184-2191, 2004.
18. NEXAVAR (sorafenib) tablets, oral [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., 2010.
19. SUTENT® (sunitinib malate) capsules, oral [package insert]. New York, NY: Pfizer Inc., 2011.
20. Votrient™ (pazopanib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2010; revised April 2010.
21. Levitzki A: PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 15(4): 229-235, 2004.
22. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K and Miyazawa K: VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRβ signaling. J Cell Sci 118(Pt 16): 3759-3768, 2005.
23. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E and Cao Y: Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117(10): 2766-2777, 2007.
24. Vakiani E and Solit DB: KRAS and BRAF: Drug targets and predictive biomarkers. J Pathol 223(2): 219-229, 2011.
25. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA and King AG: Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101(10): 1717-1723, 2009.
26. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A and Vajkoczy P: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18(2): 338-340, 2004.
27. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4): 299-309, 2005.
28. Roodhart JM, Langenberg MH, Witteveen E and Voest EE: The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3(2): 132-143, 2008.
29. Ranpura V, Pulipati B, Chu D, Zhu X and Wu S: Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens 23(5): 460-468, 2010.
30. Zhu X, Wu S, Dahut WL and Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and metaanalysis. Am J Kidney Dis 49(2): 186-193, 2007.
31. Launay-Vacher V and Deray G: Hypertension and proteinuria: A class-effect of antiangiogenic therapies. Anticancer Drugs 20(1): 81-82, 2009.
32. Hood JD, Meininger CJ, Ziche M and Granger HJ: VEGF up-regulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274(3 Pt 2): 1054-1058, 1998.
33. van Heeckeren WJ, Ortiz J, Cooney MM and Remick SC: Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25(21): 2993-2995, 2007.
34. Sane DC, Anton L and Brosnihan KB: Angiogenic growth factors and hypertension. Angiogenesis 7(3): 193-201, 2004.
35. Bobik A: The structural basis of hypertension: Vascular remodelling, rarefaction and angiogenesis/arteriogenesis. J Hypertens 23(8): 1473-1475, 2005.
36. Mourad JJ, des Guetz G, Debbabi H and Levy BI: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19(5): 927-34, 2008.
37. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE and Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11): 1129-1136, 2008.
38. Jubb AM and Harris AL: Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11(12): 1172-1183, 2010.
39. Rini BI: Hypertension as a biomarker for anti-VEGF efficacy: incidence, mechanisms, and association with clinical outcome. Kidney Cancer J 8(4): 106-117, 2011.
40. Mir O, Ropert S, Alexandre J and Goldwasser F: Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20(5): 967-970, 2009.
41. Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL and He AR: Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 40(3-4): 101-108, 2009.
42. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C and Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2): 227-230, 2009.
43. De Stefano A, Carlomagno C, Pepe S, Bianco R and De Placido S: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68(5): 1207-1213, 2011.
44. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T and Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104(4): 599-604, 2011.
45. Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A and Mikkelsen T: The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). J Clin Oncol 29(suppl): Abstract 2021, 2011.
46. Rutkowski P, Bylina E, Switaj T, Klimczak A, Falkowski S, Kroc J, Lugowska IA, Brzeskwiniewicz M, Wozniak A, Siedlecki J and Limon J: An analysis of arterial hypertension and mutational status as predictive factors for results of sunitinib (SU) therapy in gastrointestinal stromal tumors (GIST). J Clin Oncol 29(suppl): Abstract 10017, 2011.
47. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S and Miller KD: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-4678, 2008.
48. Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M and Wick W: Arterial hypertension and bevacizumab treatment in glioblastoma: No correlation with clinical outcome. J Neurooncol 97(1): 157-158, 2010.
49. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 27(8): 1227-1234, 2009.
50. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR and Tew WP: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28(2): 207-214, 2010.
51. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, brao Miziara JE, Balint B, de Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, DiMatteo S and Hanna N: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol 28(11): 1835-1842, 2010.
52. Wu S, Chen JJ, Kudelka A, Lu J and Zhu X: Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9(2): 117-123, 2008.
53. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC and Scagliotti GV: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 26(4): 650-656, 2008.
54. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R and Govindan R: Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101(9): 1543-1548, 2009.
55. Zhu X, Stergiopoulos K and Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 48(1): 9-17, 2009.
56. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH and Yankelevitz DF: Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28(19): 3131-3137, 2010.
57. Lee J, Hirsh V, Park K, Qin S, Blajman CR, Perng R, Emerson L, Langmuir PB and Manegold C: Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 28(15s): Abstract 7525, 2010.
58. De Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J and Vansteenkiste JF: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29(8): 1067-1074, 2011.
59. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA and Goss GD: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol 29(8): 1059-1066, 2011.
60. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H and Johnson BE: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11(7): 619-626, 2010.
61. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S and Hanna N: Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16(10): 2881-2889, 2010.
62. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P and von Pawel J: A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Ann Oncol 22(6): 1374-1381, 2011.
63. Scagliotti G, Vynnychenko I, Ichinose Y, Park K, Kubota K, Blackhall FH, Pirker R, Galiulin R, Ciuleanu T, Sydorenko O, Dediu M, Papai-Szekely Z, Martinez Banaclocha N, McCoy S, Yao B, Hei Y and Spigel DR: An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 29(suppl): Abstract LBA7512, 2011.
64. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW and Seymour L: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28(1): 49-55, 2010.
65. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D and Rosen O: Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 28(7S): Abstract 3039, 2010.
66. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH and Johnson DH: Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28(6): 949-954, 2010.
67. Goodwin R, Ding K, Seymour L, Lemaitre A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM and Laurie SA: Treatment-emergent hypertension and outcomes in patients with advanced non-small cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 21(11): 2220-2226, 2010.
68. Munoz J, Sanchez BE, Sharifi M, Kostoff D, Ali HY, Hanbali AS, Kuriakose P and Wollner IS: Hypertension as a clinical marker of response to bevacizumab across malignancies. J Clin Oncol 29(suppl): Abstract e16601, 2011.
69. Saloustros E, Androulakis N, Vamvakas L, Mavroudis D and Georgoulias V: Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol 3(3): 368-371, 2010.
70. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S and Rixe O: Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17(11): 3841-3849, 2011.
71. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK and Figg WD: Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29: 95, 2010.
72. van der Veldt AA, Eechoute K, Oosting S, Kappers MH, Haanen JBAG, Reyners AKL, Gelderblom H, Guchelaar H, Van Herpen C, Boven E and Mathijssen R: Single-nucleotide polymorphisms (SNPs) in endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension. J Clin Oncol 29(suppl): Abstract 4611, 2011.
73. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ and Ratain MJ: Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15(19): 6250-6257, 2009.
74. Levine MR, Wroblewski K, Dharanipragada D, Sit L, Karrison T, Seiwert TY, Cohen EE, Vokes EE and Maitland ML: Use of typical in-patient blood pressure measurements to detect bevacizumab-induced elevation in systolic pressure after the first infusion. J Clin Oncol 28(suppl): Abstract e13622, 2010.
75. Azizi M, Chedid A and Oudard S: Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358(1): 95-97, 2008.
76. Maitland ML, Karrison T, Bakris GL, Fox K, Janisch LA, Karovic S, Levine MR, House L, Wright JJ, Cohen EE, Fleming GF, Seiwert TY, Villaflor VM, Stadler WM and Ratain MJ: Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S). J Clin Oncol 29(suppl): Abstract 3016, 2011.
77. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA: BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19): 7099-7109, 2004.
78. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J and Tang C: Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and plateletderived growth factor receptor tyrosine kinase. J Med Chem 46(7): 1116-1119, 2003.
79. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A and Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12): 4774-4782, 2008.
80. Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T, Lotz R, Tontsch-Grunt U, Walter R and Hilberg F: Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 52(14): 4466-4480, 2009.
81. Nikolinakos P and Heymach JV: The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 3(6 Suppl 2): S131-S134, 2008.
82. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK and Cheung M: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7): 2012-2021, 2007.
83. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D and Anderson KC: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 103(51): 19478-19483, 2006.
84. Fujisaka Y, Yamada Y, Yamamoto N, Shimizu T, Fujiwara Y, Yamada K, Tamura T, Watanabe H, Sun YN, Bass MB and Seki M: Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 66(5): 935-943, 2010.